glp 1 formulary Indications for GLP-1/GIP RA Summary Sheet and Beyond! Payers should lean on PBMs

Other outcomes included major adverse cardiovascular events (MACE) (cardiovascular mortality, all-cause mortality, stroke, and myocardial infarction), changes in metabolic parameters, and adverse events

The first medications the FDA approved in this class were injectables, though oral GLP-1s have since made their way to the market

Hot flashes, though

doi:10.1007/s11064-025-04475-y 41

In Covid-19, variations in fasting blood glucose are considered an independent risk factor for poor prognosis and outcome in Covid-19 patients

The development of novel GLP-1 receptor agonists, with enhanced efficacy and fewer side effects, has made them an attractive choice for clinicians